Dasatinib in breast cancer: Src-ing for response in all the wrong kinases.
作者信息
Kennedy Laura C, Gadi Vijayakrishna
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Medicine, University of Washington, Seattle, WA, USA.
出版信息
Ann Transl Med. 2018 Nov;6(Suppl 1):S60. doi: 10.21037/atm.2018.10.26.
Abstract
摘要
相似文献
1
Dasatinib in breast cancer: Src-ing for response in all the wrong kinases.达沙替尼治疗乳腺癌：在错误的激酶中寻找应答的Src激酶
Ann Transl Med. 2018 Nov;6(Suppl 1):S60. doi: 10.21037/atm.2018.10.26.
2
Monitoring Src status after dasatinib treatment in HER2+ breast cancer with Zr-trastuzumab PET imaging.Zr-曲妥珠单抗 PET 显像监测曲达西他滨治疗后 HER2+乳腺癌中的Src 状态。
Breast Cancer Res. 2018 Oct 25;20(1):130. doi: 10.1186/s13058-018-1055-2.
3
Src: a potential target for the treatment of triple-negative breast cancer.Src：三阴性乳腺癌治疗的潜在靶点。
Ann Oncol. 2011 Oct;22(10):2234-40. doi: 10.1093/annonc/mdq757. Epub 2011 Feb 28.
4
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.SRC驱动抗雌激素耐药乳腺癌细胞系的生长，并且是他莫昔芬治疗获益降低的一个标志物。
PLoS One. 2015 Feb 23;10(2):e0118346. doi: 10.1371/journal.pone.0118346. eCollection 2015.
5
Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.达沙替尼减弱维利帕尼联合卡铂治疗对三阴性乳腺癌中Src 信号过度表达的抑制作用。
Cancer Chemother Pharmacol. 2019 Dec;84(6):1241-1256. doi: 10.1007/s00280-019-03962-8. Epub 2019 Sep 20.
6
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.达沙替尼是一种src和abl激酶的口服活性小分子抑制剂，可选择性抑制体外培养的基底型/“三阴性”乳腺癌细胞系的生长。
Breast Cancer Res Treat. 2007 Nov;105(3):319-26. doi: 10.1007/s10549-006-9463-x. Epub 2007 Feb 1.
7
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.Src是雌激素受体介导的反式激活水平较低的内分泌抵抗性乳腺癌中的一个潜在治疗靶点。
PLoS One. 2016 Jun 16;11(6):e0157397. doi: 10.1371/journal.pone.0157397. eCollection 2016.
8
Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.达沙替尼抑制 SRC 家族激酶和受体酪氨酸激酶：实体肿瘤的可能联合治疗方案。
Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13.
9
Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).达沙替尼抑制c-src磷酸化，并阻止过表达Syndecan结合蛋白（SDCBP）的三阴性乳腺癌（TNBC）细胞的增殖。
PLoS One. 2017 Jan 31;12(1):e0171169. doi: 10.1371/journal.pone.0171169. eCollection 2017.
10
Dasatinib : a novel therapy for breast cancer?达沙替尼：乳腺癌的新型治疗方法？
Expert Opin Investig Drugs. 2013 Jun;22(6):795-801. doi: 10.1517/13543784.2013.793308. Epub 2013 Apr 18.
引用本文的文献
1
Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications.蛋白激酶抑制剂的进展：从发现到临床应用。
Research (Wash D C). 2025 Jun 21;8:0747. doi: 10.34133/research.0747. eCollection 2025.
2
Exploration of crucial stromal risk genes associated with prognostic significance and chemotherapeutic opportunities in invasive ductal breast carcinoma.探索浸润性导管癌中与预后意义和化疗机会相关的关键基质风险基因。
J Genet Eng Biotechnol. 2025 Mar;23(1):100448. doi: 10.1016/j.jgeb.2024.100448. Epub 2024 Dec 24.
3
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.对经典抗HER治疗耐药的HER2阳性转移性乳腺癌患者新治疗策略的临床影响
Cancers (Basel). 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522.
4
Manipulating PTPRD function with ectodomain antibodies.利用外域抗体来操控 PTPRD 功能。
Genes Dev. 2023 Aug 1;37(15-16):743-759. doi: 10.1101/gad.350713.123. Epub 2023 Sep 5.
5
A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.一项针对芳香化酶抑制剂和CDK4/6抑制剂难治的转移性激素受体阳性且人表皮生长因子受体2阴性（HR+ HER2-）乳腺癌患者，使用哌柏西利、博舒替尼联合氟维司群的I期试验。
Contemp Clin Trials Commun. 2023 Mar 13;33:101110. doi: 10.1016/j.conctc.2023.101110. eCollection 2023 Jun.
6
Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer.靶向衰老作为三阴性乳腺癌的治疗机会。
Mol Cancer Ther. 2023 May 4;22(5):583-598. doi: 10.1158/1535-7163.MCT-22-0643.
7
Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development.乳腺癌细胞蛋白质组学时间进程研究表明，在内分泌耐药性发展之前，乳腺癌细胞对 Stat3 和 Src 抑制剂更为敏感。
Cancer Gene Ther. 2023 Feb;30(2):324-334. doi: 10.1038/s41417-022-00548-0. Epub 2022 Oct 20.
8
Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment.新型Src抑制剂AZD0424与MEK抑制剂联合用于癌症治疗的通路分析
Mol Oncol. 2022 Mar;16(5):1072-1090. doi: 10.1002/1878-0261.13151. Epub 2021 Dec 18.
9
Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer.三阴性乳腺癌的发病机制及潜在治疗靶点
Cancers (Basel). 2021 Jun 14;13(12):2978. doi: 10.3390/cancers13122978.
10
Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy.乳腺癌免疫治疗新疗法概述及联合治疗方案建议。
Molecules. 2020 Dec 2;25(23):5686. doi: 10.3390/molecules25235686.
本文引用的文献
1
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.紫杉醇和达沙替尼治疗转移性乳腺癌的 II 期研究。
Clin Breast Cancer. 2018 Oct;18(5):387-394. doi: 10.1016/j.clbc.2018.03.010. Epub 2018 Mar 15.
2
Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model.在4T1小鼠乳腺癌模型中，用Src抑制剂达沙替尼治疗会导致转移潜能升高。
Tumor Microenviron. 2018;1(1):30-36. doi: 10.4103/tme.tme_19_17. Epub 2018 Jan 30.
3
Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib.采用卡培他滨、口服长春瑞滨和达沙替尼联合治疗的晚期乳腺癌患者获得完全缓解。
Exp Hematol Oncol. 2018 Jan 24;7:2. doi: 10.1186/s40164-018-0094-9. eCollection 2018.
4
Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.HER2阳性癌细胞中针对曲妥珠单抗的耐药机制及其通过Src抑制的消除
Mol Cancer Ther. 2017 Jun;16(6):1145-1154. doi: 10.1158/1535-7163.MCT-16-0669. Epub 2017 Feb 21.
5
Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.达沙替尼对新诊断慢性髓性白血病患者骨稳态的脱靶效应的多参数分析
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl(Suppl):S86-92. doi: 10.1016/j.clml.2016.02.027.
6
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.TBCRC-010：达沙替尼联合唑来膦酸治疗乳腺癌骨转移的 I/II 期研究。
Clin Cancer Res. 2016 Dec 1;22(23):5706-5712. doi: 10.1158/1078-0432.CCR-15-2845. Epub 2016 May 10.
7
Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.新型口服可用的SRC/Raf/VEGFR2抑制剂SKLB646治疗三阴性乳腺癌的临床前评估
Mol Cancer Ther. 2016 Mar;15(3):366-78. doi: 10.1158/1535-7163.MCT-15-0501. Epub 2015 Dec 31.
8
The Emerging Role of ABL Kinases in Solid Tumors.ABL激酶在实体瘤中的新兴作用
Trends Cancer. 2015 Oct 1;1(2):110-123. doi: 10.1016/j.trecan.2015.07.004.
9
C-kit and PDGFRA gene mutations in triple negative breast cancer.三阴性乳腺癌中的C-kit和血小板衍生生长因子受体A（PDGFRA）基因突变
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4280-5. eCollection 2014.
10
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.博舒替尼联合芳香化酶抑制剂依西美坦：一项针对既往接受过治疗的局部晚期或转移性激素受体阳性/人表皮生长因子受体2阴性绝经后乳腺癌女性的II期试验。
Oncologist. 2014 Apr;19(4):346-7. doi: 10.1634/theoncologist.2014-0022. Epub 2014 Mar 27.
Zotero 插件